Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PMLRAR-α oncogene in acute promyelocytic leukemia

Leukemia and Lymphoma

Volumn 51, Issue 6, 2010, Pages 1108-1114

  Schinke, Carolina ^a   Goel, Swati ^a   Bhagat, Tushar D ^a   Zhou, Li ^a   Mo, Yongkai ^a   Gallagher, Robert ^a   Kabalka, George W ^b   Platanias, Leonidas C ^c   Verma, Amit ^a   Das, Bhaskar ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute promyelocytic leukemia (APL); All trans retinoic acid (ATRA); Retinoids

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; CD11 ANTIGEN; HYBRID PROTEIN; LUCIFERASE; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN;

ARTICLE; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; DNA RESPONSIVE ELEMENT; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; INFANT; METABOLISM; PATHOLOGY; SYNTHESIS; TUMOR CELL LINE;

ANTIGENS, CD11; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INFANT; LEUKEMIA, PROMYELOCYTIC, ACUTE; LUCIFERASES; MOLECULAR STRUCTURE; ONCOGENE PROTEINS, FUSION; RECOMBINANT FUSION PROTEINS; RESPONSE ELEMENTS; TRANSFECTION; TRETINOIN;

EID: 77953530664     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003786766     Document Type: Article

References (24)

1. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-3215.
2. Sanz M. Treatment of acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2006;147-155.
3. Clarke N, Germain P, Altucci L, Gronemeyer H. Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 2004;6:1-23.
4. Fernandez-Mateos A, Mateos Buron L, Martin de la Nava EM, Rubio Gonzalez R. Synthesis of CDE and BCDE molecular fragments of the limonoids havanensin and azadiradione. J Org Chem 2003;68:3585-3592.
5. Rosenberger M, Neukom C, Rosenberger M, Neukom C. Retinoic acid metabolites. 2. Total synthesis of rac-(2E, 4E,6E,8E)-3,7-dimethyl-9-(6-carboxy- 2,6-dimethyl-3-oxo-1- cyclohexen-1-yl)- 2,4,6,8-nonatetraenoic acid and rac-(2E, 4E,6E,8E)-3,7-dimethyl-9-[2,6-dimethyl-6-(hydroxymethyl)- 3-oxo-1-cyclohexen-1- yl]- 2,4,6,8-nonatetraenoic acid. J Org Chem 1982;47:1779-1782.
6. Waugh KM, Berlin KD, Ford WT, et al. Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4, 4-dimethylthiochroman-6-ylmethyl ketone 1,1-dioxide and ethyl (E)-p-[2-(4,4-dimethylthiochroman-6-yl)propenyl]benzoate. J Med Chem 1985;28:116-124.
7. Das B, Kabalka G. Design and synthesis of (E)- 4-((3- ethyl-2,4,4-trimethylcyclohex-2-enylidene)methyl)benzoic acid. Tetrahedron Lett 2008;49:4695.
8. Um SJ, Kwon YJ, Han HS, et al. Synthesis and biological activity of novel retinamide and retinoate derivatives. Chem Pharm Bull 2004;52:501-506.
9. Minucci S, Zand DJ, Dey A, et al. Dominant negative retinoid X receptor beta inhibits retinoic acid-responsive gene regulation in embryonal carcinoma cells. Mol Cell Biol 1994;14:360-372.
10. Alsayed Y, Uddin S,Mahmud N, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001;276:4012-4019.
11. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 1995;375:377-382.
12. Klaholz BP, Mitschler A, Moras D. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J Mol Biol 2000;302:155-170.
13. Pogenberg V, Guichou JF, Vivat-Hannah V, et al. Characterization of the interaction between retinoic acid receptor/ retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J Biol Chem 2005;280:1625-1633.
14. Bourguet W, Vivat V,Wurtz JM, Chambon P, Gronemeyer H, Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 2000;5:289-298.
15. Teng M, Duong TT, Klein ES, Pino ME, Chandraratna RA. Identification of a retinoic acid receptor alpha subtype specific agonist. J Med Chem 1996;39:3035-3038.
16. Miwako I, Kagechika H. Tamibarotene. Drugs Today 2007; 43:563-568.
17. Ohnishi K. PML-RAR alpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol 2007;12:313-317.
18. de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 2007;6: 811-820.
19. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3:950-964. (Pubitemid 39534319)
20. Lu XP, Fanjul A, Picard N, et al. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. NatMed 1997;3:686-690.
21. Cincinelli R, Dallavalle S, Nannei R, et al. Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. J Med Chem 2005;48: 4931-4946.
22. Holmes WF, Soprano DR, Soprano KJ. Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines. J Cell Physiol 2004;199:317-329.
23. Xu QH, Konta T, Furusu A, et al. Transcriptional induction of mitogen-activated protein kinase phosphatase 1 by retinoids - selective roles of nuclear receptors and contribution to the antiapoptotic effect. J Biol Chem 2002;277:41693-41700.
24. AltucciL,Rossin A, RaffelsbergerW,ReitmairA,ChomienneC, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. NatMed 2001;7:680-686.